Literature DB >> 15818738

Effects of Chinese traditional compound, JinSanE, on expression of TGF-beta1 and TGF-beta1 type II receptor mRNA, Smad3 and Smad7 on experimental hepatic fibrosis in vivo.

Shi-Ling Song1, Zuo-Jiong Gong, Quan-Rong Zhang, Tuan-Xin Huang.   

Abstract

AIM: The transforming growth factor-beta (TGF-beta)/Smad signaling pathway system plays a prominent role in the control of cell growth and extracellular matrix formation in the progression of liver fibrogenesis. Smad proteins can either positively or negatively regulate TGF-beta responses. In this study, the therapeutic effects of Chinese traditional compound decoction, JinSanE, and the changes of TGF-beta/Smad signaling pathway system in carbon tetrachloride (CCl(4))-induced rat experimental liver fibrosis were examined.
METHODS: Seventy-two healthy Wistar rats were assigned to groups including normal control group, CCl(4) model group, JinSanE treatment group I and JinSanE treatment group II. Each group contained 18 rats. All groups, except the normal control group, received CCl(4) subcutaneous injection for 8 wk. Rats in JinSanE groups I and II were orally treated with JinSanE daily at the 1(st) and 5(th) wk, respectively, after exposure to CCl(4). The expression of TGF-beta1 and TGF-beta1 type II receptor (TRII) mRNA in the liver was determined by reverse transcription polymerase chain reaction, and the expression of TGF-beta1, Smad3 and Smad7 by immunohistochemistry. The liver histopathology was also examined by HE staining and observed under electron microscope. The activities of several serum fibrosis-associated enzymes, alanine aminotransferase (ALT), aspartate aminotransferase (AST), the levels of serum hyaluronic acid (HA) were assayed.
RESULTS: Hepatic fibrosis caused by CCl(4) was significantly inhibited in the JinSanE-treated groups. The degrees of necrosis/degeneration and fibrosis scores were significantly lower in the JinSanE-treated groups than in the model control group. The expression of TGF-beta1, TRII and Smad3 was significantly higher in the model group than that in the JinSanE-treated groups, and the active/total TGF-beta1 ratio in the JinSanE groups was suppressed. Expression of TRII mRNA and Smad3 proteins showed a distribution pattern similar to that of TGF-beta1 with a direct correlation in terms of the degree of hepatic fibrosis. The amount of positive staining Smad7 cells was significantly less in the model group than in the JinSanE-treated groups and the normal group. The contents of ALT, AST and HA were significantly lower in the JinSanE-treated groups than those in the model group.
CONCLUSION: Traditional Chinese medicine, JinSanE, prevents the progression of hepatic damage and fibrosis through the inhibition of TGF-beta1, TRII and Smad3 signal proteins, and increases expression of Smad7 signal protein in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15818738      PMCID: PMC4305811          DOI: 10.3748/wjg.v11.i15.2269

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  Effects of Yigan Decoction on proliferation and apoptosis of hepatic stellate cells.

Authors:  Xi-Xian Yao; You-Wei Tang; Dong-Mei Yao; He-Ming Xiu
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

2.  Genomic locus and promoter region of rat Smad7, an important antagonist of TGFbeta signaling.

Authors:  M Stopa; V Benes; W Ansorge; A M Gressner; S Dooley
Journal:  Mamm Genome       Date:  2000-02       Impact factor: 2.957

3.  Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats.

Authors:  I Shimizu; Y R Ma; Y Mizobuchi; F Liu; T Miura; Y Nakai; M Yasuda; M Shiba; T Horie; S Amagaya; N Kawada; H Hori; S Ito
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Smad6 inhibits signalling by the TGF-beta superfamily.

Authors:  T Imamura; M Takase; A Nishihara; E Oeda; J Hanai; M Kawabata; K Miyazono
Journal:  Nature       Date:  1997-10-09       Impact factor: 49.962

5.  Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis.

Authors:  J Napoli; D Prentice; C Niinami; G A Bishop; P Desmond; G W McCaughan
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

6.  Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.

Authors:  M Okuno; K Akita; H Moriwaki; N Kawada; K Ikeda; K Kaneda; Y Suzuki; S Kojima
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

7.  Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats.

Authors:  D Roulot; A M Sevcsik; T Coste; A D Strosberg; S Marullo
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

8.  Regulating effect of Chinese herbal medicine on the peritoneal lymphatic stomata in enhancing ascites absorption of experimental hepatofibrotic mice.

Authors:  Ji-Cheng Li; Shi-Ping Ding; Jian Xu
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

Review 9.  Roles of TGF-beta in hepatic fibrosis.

Authors:  Axel M Gressner; Ralf Weiskirchen; Katja Breitkopf; Steven Dooley
Journal:  Front Biosci       Date:  2002-04-01

10.  Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts.

Authors:  E Balza; L Borsi; G Allemanni; L Zardi
Journal:  FEBS Lett       Date:  1988-02-08       Impact factor: 4.124

View more
  3 in total

1.  Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats.

Authors:  Wen-Chuan Lin; Shu-Ching Kuo; Wei-Lii Lin; Hsun-Lang Fang; Bor-Chen Wang
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

2.  Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway.

Authors:  Jin-Xing Du; Ming-Yu Sun; Guang-Li Du; Feng-Hua Li; Cheng Liu; Yong-Ping Mu; Gao-Feng Chen; Ai-Hua Long; Yan-Qin Bian; Jia Liu; Cheng-Hai Liu; Yi-Yang Hu; Lie-Ming Xu; Ping Liu
Journal:  BMC Complement Altern Med       Date:  2012-04-03       Impact factor: 3.659

3.  Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins.

Authors:  María del Pilar Alatorre-Carranza; Alejandra Miranda-Díaz; Irinea Yañez-Sánchez; Oscar Pizano-Martínez; José M Hermosillo-Sandoval; Mónica Vázquez-Del Mercado; Sebastián Hernández-Hoyos; Ricardo Martínez-Abundis; Mary Fafutis-Morris; Jorge Segura-Ortega; Vidal Delgado-Rizo
Journal:  BMC Gastroenterol       Date:  2009-10-31       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.